Heart Inflammation and Mental Stress Study (HIMS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03695146 |
Recruitment Status :
Recruiting
First Posted : October 3, 2018
Last Update Posted : September 28, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypertension | Behavioral: Paced breathing Behavioral: Active relaxation | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 144 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Basic Science |
Official Title: | Heart Inflammation and Mental Stress Study |
Actual Study Start Date : | August 19, 2019 |
Estimated Primary Completion Date : | December 2023 |
Estimated Study Completion Date : | December 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Paced breathing
Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals in this arm will engage in a paced breathing. Initial respiratory rate will be measured with a transducer. Participants will be connected to a paced breathing device (RESPERATE) that will gradually reduce the pace of audio tones presented to those individuals from spontaneous breathing rate down to 6 - 8 breaths per minute.
|
Behavioral: Paced breathing
Individuals will be fitted with a respiratory transducer and receive auditory tones with which to pace their rate of inspiration and expiration in the experimental group. |
Active Comparator: Relaxing music
Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes. Individuals will be provided with an audio device that plays soothing/relaxing music at a similar range (beats per minute) of the auditory signal presented during the experimental condition. Subjects will not be instructed how to breathe in this arm.
|
Behavioral: Active relaxation
Individuals will be provided with headphones while resting quietly listening to relaxing tones/music. |
No Intervention: No intervention
Individuals will be asked to sit in a quiet room while sensors collect their heart rate, respiratory rate and blood pressure for approximately 45 minutes.
|
- Change in heart rate variability [ Time Frame: Baseline, pre-intervention and up to 60 minutes post-intervention ]Heart rate variability will be measured using a standard electrocardiogram to detect variability in R -to-R intervals.
- Change in cytokine expression in peripheral blood mononuclear cells [ Time Frame: Baseline, pre-intervention and up to 60 minutes post-intervention ]Peripheral blood will be drawn and mononuclear cells isolated and incubated with lipopolysaccharide to induce inflammatory cytokine expression. The change in cytokine expression will be quantified as a function of time.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
- pre-hypertension screening.
- HIV-antibody testing.
Exclusion criteria:
- current use of anti-lipid, antihypertensive, or heart rate altering medications;
- current or lifetime history of cardiovascular disease diagnosis or treatment including pulmonary stenosis, heart valve abnormalities and hypertension;
- current or lifetime diagnoses of cancer, kidney/liver disease, hypertension, Type 1 or Type 2 diabetes;
- history of trauma, cerebral infarction or hemorrhage;
- current diagnosis and/or treatment for hypertension;
- severe cognitive impairment;
- current treatment or diagnosis of psychiatric illness;
- metal implants or debris within the body; or pregnancy;
- body mass index > 35;
- use of hormone replacement therapy; and current smoker.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03695146
Contact: Roger C McIntosh, Ph.D. | 305-243-2047 | r.mcintosh@miami.edu | |
Contact: Katie Dillon, M.S. | 305-243-1266 | kxd@miami.edu |
United States, Florida | |
University of Miami | Recruiting |
Miami, Florida, United States, 33136 | |
Contact: Roger C McIntosh, PhD 305-243-2047 ext 3 r.mcintosh@miami.edu | |
Principal Investigator: Roger C McIntosh, PhD |
Principal Investigator: | Roger C McIntosh, Ph.D. | University of Miami, College of Arts and Sciences |
Responsible Party: | Roger McIntosh, Assistant Professor, University of Miami |
ClinicalTrials.gov Identifier: | NCT03695146 |
Other Study ID Numbers: |
20180631 K01HL139722-01 ( U.S. NIH Grant/Contract ) |
First Posted: | October 3, 2018 Key Record Dates |
Last Update Posted: | September 28, 2022 |
Last Verified: | September 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
High blood pressure HIV |
Inflammation Stress, Psychological Pathologic Processes Behavioral Symptoms |